Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term outcome of adjustable transobturator male system for stress urinary incontinence in the Iberian multicentre study.
Angulo JC, Virseda-Chamorro M, Arance I, Ruiz S, Ojea A, Carballo M, Rodríguez A, Pereira J, Teyrouz A, Rebassa M, Escribano G, Teba F, Celada G, Madurga B, Martins FE, Mendes PA, Cruz F. Angulo JC, et al. Among authors: ojea a. Neurourol Urodyn. 2020 Aug;39(6):1737-1745. doi: 10.1002/nau.24410. Epub 2020 Jun 4. Neurourol Urodyn. 2020. PMID: 32496606
Treatment of male stress urinary incontinence with the adjustable transobturator male system: Outcomes of a multi-center Iberian study.
Angulo JC, Cruz F, Esquinas C, Arance I, Manso M, Rodríguez A, Pereira J, Ojea A, Carballo M, Rabassa M, Teyrouz A, Escribano G, Rodríguez E, Teba F, Celada G, Madurga B, Álvarez-Ossorio JL, Marcelino JP, Martins FE. Angulo JC, et al. Among authors: ojea a. Neurourol Urodyn. 2018 Apr;37(4):1458-1466. doi: 10.1002/nau.23474. Epub 2018 Jan 9. Neurourol Urodyn. 2018. PMID: 29315765
Lifestyle factors and oncogenic papillomavirus infection in a high-risk male population.
Lopez-Diez E, Perez S, Carballo M, Iñarrea A, de la Orden A, Castro M, Rodríguez M, Almuster S, Montero R, Perez M, Sanchez J, Ojea A. Lopez-Diez E, et al. Among authors: ojea a. PLoS One. 2017 Sep 12;12(9):e0184492. doi: 10.1371/journal.pone.0184492. eCollection 2017. PLoS One. 2017. PMID: 28898279 Free PMC article.
A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
Ojea A, Nogueira JL, Solsona E, Flores N, Gómez JM, Molina JR, Chantada V, Camacho JE, Piñeiro LM, Rodríguez RH, Isorna S, Blas M, Martínez-Piñeiro JA, Madero R; CUETO Group (Club Urológico Español De Tratamiento Oncológico). Ojea A, et al. Eur Urol. 2007 Nov;52(5):1398-406. doi: 10.1016/j.eururo.2007.04.062. Epub 2007 Apr 27. Eur Urol. 2007. PMID: 17485161 Clinical Trial.
Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
Martínez-Piñeiro L, Portillo JA, Fernández JM, Zabala JA, Cadierno I, Moyano JL, Solsona E, Unda M, Beardo P, Rodríguez-Molina J, Chantada V, Palou J, Muntañola P, Alonso Dorrego JM, Pérez-Garcia FJ, Silva JM, Chesa N, Montesinos M, Ojea A, Madero R, Martínez-Piñeiro JA. Martínez-Piñeiro L, et al. Among authors: ojea a. Eur Urol. 2015 Aug;68(2):256-62. doi: 10.1016/j.eururo.2015.02.040. Epub 2015 Mar 18. Eur Urol. 2015. PMID: 25794457 Clinical Trial.
Prevalence and concordance of high-risk papillomavirus infection in male sexual partners of women diagnosed with high grade cervical lesions.
López Diez E, Pérez S, Iñarrea A, de la Orden A, Castro M, Almuster S, Tortolero L, Rodríguez M, Montero R, Ojea A. López Diez E, et al. Among authors: ojea a. Enferm Infecc Microbiol Clin. 2017 May;35(5):273-277. doi: 10.1016/j.eimc.2016.02.014. Epub 2016 Mar 20. Enferm Infecc Microbiol Clin. 2017. PMID: 27004428 English, Spanish.
43 results